{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'Section# and Name', 'Description of Change', 'Brief Rationale', 'Table 2 and', 'reported by participants at', 'participants in the study.', 'Schedule of Activities for', 'each visit starting with Day 1', 'Participants Permanently', '(randomization visit) and after', 'Discontinuing Study', 'study treatment discontinuation', 'Treatment, Table 3', 'Section 2: Schedule of', 'Added renal ultrasound for', 'Per the DIL, renal ultrasound is', 'Activities for Participants', 'ADPKD participants upon', 'mandated for all participants', 'Permanently Discontinuing', 'discontinuation of study', 'with history of ADPKD who', 'Study Treatment, Table 3', 'treatment.', 'have discontinued study', 'treatment.', 'Edited Risk Assessment', 'Section 3.3.1 Risk Assessment', 'Updated risk assessment table', 'with language related to', 'information to align with', 'Investigator Brochure update.', \"version 10 of the Investigator's\", 'Brochure.', 'Section 4. Objectives and', 'Added secondary and', 'Endpoints', 'exploratory endpoints and', 'New objectives and endpoints', 'were added to evaluate the', 'objectives related to BP', 'exacerbations and concomitant', 'effect of study treatment on', 'BP.', 'medications', 'Section 4. Objectives and', 'Revised secondary endpoints', 'Endpoints were revised to align', 'Endpoints', 'for work productivity and', 'with the type of data captured', 'regular daily activity', 'in WPAI-ANS-CPV', 'impairment to quantify', 'questionnaire.', 'participant employment status', 'and remove mean hours', 'captured on WPAI-ANS-CPV', 'Section 4. Objectives and', 'Amended exploratory', 'Exploratory objective amended', 'Endpoints', 'objectives for Hgb change to', 'to fix the administrative error', 'evaluate participants achieving', '(typo) from the initial protocol.', 'a Hgb increase of >1.0g/dL', 'instead of >1.2g/dL', 'Section 4. Objectives and', 'Updated the exploratory', 'Objective and endpoints were', 'Endpoints', 'objective to capture time to first', 'updated to additionally analyse', 'rhEPO and Transfusion use.', 'the use of rhEPO and', 'Transfusion in the study.', 'Section 6.1 Inclusion Criteria', 'Edited inclusion crtierion #5 to', 'Inclusion criterion to provide', '#5', 'provide clarity for requirements', 'further clarity on appropriate', 'of compliance with oral iron', 'compliance with type and dose', '4']['2016N298481_02', 'CONFIDENTIAL', '205270', 'Section# and Name', 'Description of Change', 'Brief Rationale', 'dosing prior to Day 1, and', 'of oral iron prior to', 'removed the need for stable', 'randomization.', 'iron dose prior to screening.', 'Section 6.2 Exclusion Criteria', 'Edited exclusion criterion #13', 'Broadened exclusion to include', '#13', 'edited to include use of', 'participation in a study with an', 'investigational device', 'investigational agent or device', 'Section 6.2 Exclusion Criteria', 'Added exclusion criterion #22', 'Additional criterion added to', '#22', 'for uncontrolled hypertension', 'exclude participants with', 'uncontrolled hypertension as', 'worsening of hypertension has', 'been added to the list of AESI', 'for daprodustat per IB Version', '10', 'Table 6. Study Treatment', 'Instructions to repeat and', 'Language added to align with', 'Dosing Algorithm', 'average HemoCue Hgb', 'the IRT system programming.', 'assessment for Hgb <8.5 g/dL', 'Section 8.1 Discontinuation of', 'Added information regarding', 'Study treatment must be', 'Study Treatment', 'discontinuation of study', 'discontinued in participants', 'treatment in participants with', 'with ADPKD who experience', 'ADPKD.', 'greater than expected', 'worsening of kidney function', 'and/or cyst enlargement with', 'no other cause or clinical', 'scenario identified.', 'Section 8.2 Withdrawal from', 'Added language related to', 'To align with the ICF and', 'the Study', 'alternative methods of follow-', 'provide information regarding', 'up', 'additional methods of follow-up', 'for participants unwilling to', 'perform study clinic visits.', 'Section 8.3 Lost to Follow Up', 'Added language regarding', 'To provide further guidance on', 'alternative methods of follow-', 'evaluation of participant status', 'up for participants potentially', 'after the participant is lost to', 'lost to follow up.', 'follow up.', 'Section 9.1 Screening and', 'Added language regarding', 'To ensure sites they may', 'Critical Baseline Assessments', 'retests with a new blood', 'retest Hgb with a new blood', 'sample and entering HemoCue', 'sample for the day 1 visit.', 'Hgb values into the IRT system', 'Additional clarification provided', 'regarding data entry criteria to', 'capture HemoCue Hgb values', '5']\n\n###\n\n", "completion": "END"}